Research
Trial on Statins for Cirrhosis Won't End Debate Anytime Soon
The Brief
- The phase III SACRED trial found statin therapy came close to, but did not reach, statistical significance in lowering risks of hepatic decompensation and liver cancer in patients with compensated cirrhosis.
- The primary result comes from an intention-to-treat analysis.
- MedPage Today's coverage was filed from the AASLD meeting and says the debate over statins in cirrhosis will continue.
Why it matters
Statins are widely used for cardiovascular risk and are being studied as a possible way to slow cirrhosis complications, so a near-miss result leaves clinicians without a clear answer on whether to prescribe them to patients with compensated cirrhosis.
Who’s affected
- hepatologists and clinicians treating patients with cirrhosis
- patients with compensated cirrhosis and their care teams
(MedPage Today) -- Statin therapy delivered a statistical near miss at lowering risks of hepatic decompensation and liver cancer in patients with compensated cirrhosis, the phase III SACRED trial showed. In an intention-to-treat analysis, 8.97...